<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112211</url>
  </required_header>
  <id_info>
    <org_study_id>TAODOXYIMAGE</org_study_id>
    <nct_id>NCT05112211</nct_id>
  </id_info>
  <brief_title>Multi-model Image of Doxycycline in TAO</brief_title>
  <official_title>A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated&#xD;
      Ophthalmopathy by multi-modal image.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid Associated Ophthalmopathy is one of autoimmune orbital diseases characterized by&#xD;
      enlargement of the extraocular muscles and increase in fatty or/and orbit connective tissue&#xD;
      volume affecting the appearance and visual function of the eyes. Different degrees of&#xD;
      exophthalmos, eyelid aperture, lid retraction and lid lag are common symptoms apprearing in&#xD;
      TAO. The improvement of exophthalmos is usually measured with Hertel instrument and the&#xD;
      change of eyelid is measured with millimeter ruler. All these measurements are subjective,&#xD;
      low reliable and less accurate.&#xD;
&#xD;
      TAO can be classified into active phase and inactive phase according to the activity score&#xD;
      and wait-and-see or surgery are widely chosen for patients in inactive phase. But still a&#xD;
      progression and reoccurrence can be a big challenge for ophthalmologists. This is a&#xD;
      perspective cohort study to evaluate the efficacy of doxycycline in TAO by multi-model image.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients diagnosed by Thyroid-Associated Ophthalmopahty</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Assessors who calculate the changes of the images are masked of the diagnosis and treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change of extraocular muscle volume and orbital fat volume by MRI</measure>
    <time_frame>at month 6</time_frame>
    <description>3D MRI image will be established and the volume of extraocular muscle and orbital fat will be calculated by the same advanced programmer who is blinded of the pre- or post- treatment images order. A higher score means a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of exophthalmos</measure>
    <time_frame>at month 6</time_frame>
    <description>exophthalmos will be measured by the same investigator using the same Hertel instrument.&#xD;
A higher change of exphthalmos means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Quality of Life</measure>
    <time_frame>at month 6</time_frame>
    <description>The score of quality of life will be assessed by the same investigator using GO-QoL. The better change of quality of life means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of eyelid aperture, lid retraction and lid lag</measure>
    <time_frame>at month 6</time_frame>
    <description>the values will be measured by the same investigator using the same millimeter ruler and the higher values change, the better the outcome is.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Thyroid Associated Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients administrated with doxycycline tablets 100mg orally per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Hyclate</intervention_name>
    <description>patients administrated with doxycycline tablets 100mg orally per day</description>
    <arm_group_label>doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age 18-70 years old&#xD;
&#xD;
          -  Diagnosed with TAO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sight-threatening TAO with dysthyroid optic neuropathy&#xD;
&#xD;
          -  Allergy of tetracycline&#xD;
&#xD;
          -  Have contraindications of MRI(metal pacemaker, fake teeth, foreign body and other&#xD;
             materials which will disturb the examination)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Liang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Liang</last_name>
    <phone>（86）-87330402</phone>
    <email>liangdan@gzzoc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxi Chen</last_name>
    <phone>（86）-87330402</phone>
    <email>chenyx293@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang</last_name>
      <phone>（86）-87330402</phone>
      <email>liangdan@gzzoc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dan Liang</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Doxycycline</keyword>
  <keyword>Thyroid Associated Ophthalmopathy</keyword>
  <keyword>Extraorbital muscle</keyword>
  <keyword>Orbit fat volume</keyword>
  <keyword>Multi-modal image</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

